Evaluation of a novel line-probe assay for genotyping-based diagnosis of Mycobacterium tuberculosis in Thailand

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 7, 2015, Pages 817-822

  Rienthong, S ^a   Boonin, C ^a   Chaiyasirinrote, B ^b   Satproedprai, N ^a   Mahasirimongkol, S ^a   Yoshida, H ^c   Kondo, Y ^c   Namwat, C ^a   Rienthong, D ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b TB HIV Research Foundation   (Thailand)

^c Nipro Corporation   (Japan)

Author keywords

Drug susceptibility testing; M. Tuberculosis; Rapid test

Indexed keywords

ISONIAZID; LEVOFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; DIAGNOSTIC KIT; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ACCUPROBE ASSAY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CONTROLLED STUDY; CULTURE MEDIUM; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA PROBE; DNA SEQUENCE; GENE MUTATION; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; LINE PROBE ASSAY; MYCOBACTERIUM AVIUM; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PNCA GENE; PRIORITY JOURNAL; RAPID TEST; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE; THAILAND; TUBERCULOSIS; CLASSIFICATION; DIAGNOSTIC KIT; EVALUATION STUDY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; SPUTUM;

ANTIBIOTICS, ANTITUBERCULAR; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FLUOROQUINOLONES; GENOTYPE; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; REAGENT KITS, DIAGNOSTIC; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SPUTUM; THAILAND;

EID: 84930815121     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0311     Document Type: Article

References (32)

1. Hoek K G, Van Rie A, van Helden P D, Warren R, Victor T. Detecting drug-resistant tuberculosis: importance of rapid testing. Mol Diagn Ther 2011; 15: 189-194.
2. Pai M, Minion J, Sohn H, Zwerling A, Perkins MD. Novel and improved techologies for tuberculosis diagnosis: progress and challenges. Clin Chest Med 2009; 30: 701-716.
3. Drobniewski F, Nikolayevskyy V, Maxeiner H, et al. Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementation. BMC Med 2013; 11: 190.
4. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 System for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 2010; 48: 300-301.
5. Piersimoni C, Mustazzolu A, Giannoni F, Bornigia S, Gherardi G, Fattorini L. Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 System using a reduced inoculum. J Clin Microbiol 2013; 51: 291-294.
6. Simons S O, van Ingen J, van der Laan T, et al. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 2012; 50: 428-434.
7. Caminero J A, Sotgiu G, Zumla A, Migliori G B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629.
8. Mitarai S, Kato S, Ogata H, et al. Comprehensive multicenter evaluation of a new line probe assay kit for identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2011; 50: 884- 890.
9. Drake T A, Hindler J A, Berlin O G, Bruckner D A. Rapid identification of Mycobacterium avium complex in culture using DNA probes. J Clin Microbiol 1987; 25: 1442-1445.
10. Saito H, Tomioka H, Sato K, et al. Identification and partial characterization of Mycobacterium avium and Mycobacterium intracellulare by using DNA probes. J Clin Microbiol 1989; 27: 994-997.
11. Tortoli E, SimonettiMT, Lavinia F. Evaluation of reformulated chemiluminescent DNA probe (AccuProbe) for culture identification of Mycobacerium kansasii. J Clin Microbiol 1996; 34: 2838-2840.
12. Hazbón M H, Brimacombe M, Bobadilla del Valle M, et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006; 50: 2640-2649.
13. Ristola M A, von Reyn C F, Arbeit R D, et al. High rates of disseminated infection due to non-tuberculous mycobacteria among AIDS patients in Finland. J Infect 1996; 39: 61-67.
14. Jones D, Havlir D V. Non-tuberculous mycobacteria in the HIV-infected patient. Clin Chest Med 2002; 23: 665-674.
15. Chetchotisakd P, Kiertiburanakul S, Mootsikapun P, Assanasen S, Chaiwarith R, Anunnatsiri S. Disseminated non-tuberculous mycobacterial infection in patients who are not infected with HIV in Thailand. Clin Infect Dis 2007; 45: 421-427.
16. Morgan M, Kalantri S, Flores L, Pai M. A commercial lineprobe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: A systematic review and metaanalysis. BMC Infect Dis 2005; 5: 62.
17. Hirano K, Abe C, Takahashi M. Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by lineprobe assay. J Clin Microbiol 1999; 37: 2663-2666.
18. Anek-Vorapong R, Sinthuwattanawibool C, Podewils L J, et al. Validation of the GenoType MTBDRplus assay for detection of MDR-TB in a public health laboratory in Thailand. BMC Infect Dis 2010. 10: 123.
19. Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. In: Hatfull G F, Jabobs W R, eds. Molecular genetics of mycobacteria. Washington, DC, USA: American Society for Microbiology, 2000: pp 234-254.
20. Kelley C L, Rouse D A, Morris S L. Analysis of ahpC gene mutations in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 2057-2058.
21. Ando H, Miyoshi-Akiyama T, Watanabe S, Kirikae T. A silent mutation in mabA confers isoniazid resistance on Mycobacteriumtuberculosis.Mol Microbiol 2014; 91: 538-547.
22. Ando H, Kitao T, Miyoshi-Akiyama T, Kato S, Mori T, Kirikae T. Downregulation of katG expression is associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 2011; 79: 1615-1628.
23. Chen J, Chen Z, Li Y, et al. Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China. Braz J Infect Dis 2012; 16: 136-141.
24. Guillemin I, Jarlier V, Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother 1998; 42: 2084-2088.
25. Ando H, Mitarai S, Kondo Y, et al. Evaluation of a line-probe assay for the rapid detection of gyrA mutations associated with fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis. J Med Microbiol 2011; 60: 184-188.
26. Malik S, Willby M, Sikes D, Tsodikov O V, Posey J E. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLOS ONE 2012; 7: e39754.
27. Kim H, Nakajima C, Kim Y U, Yokoyama K, Suzuki Y. Influence of lineage-specific amino acid dimorphisms in gyrA on Mycobacterium tuberculosis resistance to fluoroquinolones. Jpn J Infect Dis 2012; 65: 72-74.
28. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: A review. Int J Tuberc Lung Dis 2003; 7: 6-21.
29. Cheng S J, Thibert L, Sanchez T, Heifets L, Zhang Y. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother 2000; 44: 528-532.
30. Hirano K, Takahashi M, Kazumi Y, Fukasawa Y, Abe C. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tubercle Lung Dis 1998; 78: 117-122.
31. Sreevatsan S, Pan X, Zhang Y, Kreiswirth B N, Musser J M. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 1997; 41: 636-640.
32. Jonmalung J, Prammananan T, Leechawengwongs M, Chaiprasert A. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol 2010; 10: 223.